Author response for "<scp>Cost‐Utility</scp> Analysis of Semaglutide for type 2 diabetes after its Addition to the National Medical Insurance System in China" Shanshan Hu, Shengsheng Gu, Chendong Qi, Shuowen Wang, Fengdan Qian, Chenyang Shi, Guorong Fancrossref（2022）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
